psalexa
P&S Market Research - A market research firm

Anxiety Disorders Therapeutics Pipeline Analysis

Anxiety Disorders Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11170
Available Format:

Anxiety disorders involves a person experiencing more than temporary worry or fear. For a person with an anxiety disorder, the anxiety does not go away and can get worse over a period of time. The feelings can interfere with daily activities such as job performance, school work, and relationships. Anxiety is a normal reaction to stress and can be beneficial in some situations. It can alert a person about any future dangers, thereby helping them to prepare and pay attention. Anxiety disorders differ from normal feelings of nervousness or anxiousness, and involve excessive fear or anxiety. Anxiety disorders are the most common of mental disorders and affect nearly 30% of adults at some point in their lives. There are several types of anxiety disorders such as generalized anxiety disorder, panic disorder, phobias, specific phobia, agoraphobia, social anxiety disorder and separation anxiety disorder. Some of the drug candidates of anxiety disorders pipeline include, but are not limited to, SRX246, JNJ-42165279 and AZ 12320927.

Some of the companies having drugs in the anxiety disorders pipeline include Lundbeck A/S, CeNeRx BioPharma, and Addex Therapeutics Ltd.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry